Top

Published in:

01-06-2010 | Review

Treatment strategies for chemotherapy-induced peripheral neuropathy: potential role of exercise

Authors: Karen Y. Wonders, Beverly S. Reigle, Daniel G. Drury

Published in: Oncology Reviews | Issue 2/2010

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common, dose-limiting effect of cancer therapy that often has negative implications on a patient’s quality of life. The pain associated with CIPN has long been recognized as one of the most difficult types of pain to treat. Historically, much effort has been made to explore pharmacological therapies aimed at reducing symptoms of CIPN. While many of these agents provide a modest relief in the symptoms of peripheral neuropathy, many have been shown to have additional negative side effects for cancer patients. Therefore, the authors suggest exercise rehabilitation as one lifestyle modification that may positively impact the lives of patients with CIPN. To our knowledge, there are currently no published clinical trials examining the role of exercise in preserving neurological function following chemotherapy. However, investigations using low-to-moderate intensity exercise as an intervention in patients with diabetic peripheral neuropathy and hereditary motor and sensory neuropathies have produced promising results. Given that cancer patients appear to tolerate exercise, it seems plausible that exercise rehabilitation could be used as an effective strategy to minimize CIPN-induced detriments to quality of life.

American Cancer Society (2009) Cancer facts & figures 2009. Author, Atlanta, GA

National Heart, Lung, and Blood Institute (2008) NHLBI fact book, fiscal year 2007. Author, Bethesda, MD

National Cancer Institute (2009) Office of Cancer Survivorship. http://dccps.nci.nih.gov/ocs/researcher_factsheet.pdf. Retrieved 5 December 2009

Ganz PA (2007) Cancer survivorship: today and tomorrow. Springer, New York, pp 1–7

Lind J (1992) Tumor cell growth and cell kinetics. Semin Oncol Nurs 8(1):3–9PubMed

Rieger PT (2006) Cancer biology and implications for treatment. Clin J Oncol Nurs 10(4):457–460PubMed

Honea N, Brant J, Beck SL (2007) Treatment-related symptom clusters. Sem Oncol Nurs 23(2):142–151

Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249:9–17PubMed

Antonine JC, Camdessanche JP (2007) Peripheral nervous system involvement in patients with cancer. Lancet Neurol 6:75–86

10.

Kaley TJ, DeAngelis LM (2009) Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol 145:3–14PubMed

11.

Stubblefield MD, Burstein HJ, Burton AW, Custodio CM, Deng GE, Ho M et al. (2009) NCCN task force report: management of neuropathy in cancer. J NCCN 7:S-1-28

12.

Woolf CJ (2004) Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 140:441–445PubMed

13.

Horowitz SH (2007) The diagnostic workup of patients with neuropathic pain. Med Clin N Am 91:21–30PubMed

14.

National Health & Medical Research Council (1999) Acute pain management: scientific evidence. Commonwealth of Australia, Australia

15.

Verstappen CP, Heimans JJ, Hoekman K, Postma TJ (2003) Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs 63(15):1549–1563PubMed

16.

Visovsky C (2003) Chemotherapy-induced peripheral neuropathy. Cancer Investig 21(3):439–451

17.

Wolf CJ, Mannion RJ (1999) Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 353:1959–1964

18.

Reyes-Gibby CC, Marrow PK, Buzdar A, Shete S (2009) Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel. J Pain 10:1146–1150PubMed

19.

Tulub AA, Stefanov VE (2001) Cisplatin stops tubulin assembly into microtubules. A new insight into the mechanisms of antitumor activity of platinum complexes. Int J Biol Macromol 28:191–198PubMed

20.

Benoit E, Brienza S, Dubois JM (2006) Oxaliplatin, an anticancer agent that affects both Na+ and K+ channels in frog peripheral myelinated axons. Gen Physiol Biophys 25:263–276PubMed

21.

Scadding JW, Kiltzenburg M (2006) Painful peripheral neuropathies. In: McMahon SB, Koltzenburg M (eds) Wall and Melzacks, textbook of pain, 5th edn. Elsevier Churchill Livingstone, Philadelphia, PA, pp 973–999

22.

Jensen TS, Baron R (2003) Translation of symptoms and signs into mechanisms of neuropathic pain. Pain 102:13–18

23.

Ahmad M, Goucke CR (2002) Management strategies for the treatment of neuropathic pain in the elderly. Drug Aging 19:929–945

24.

Bakitas MA, Smith E, Cohen J, Fadul C (2004) Measurement issues in chemotherapy-induced peripheral neuropathy. In: Paper presented at the international conference on the mechanisms and treatment of neuropathic pain, Bermuda, November 4–6, 2004

25.

Grothey A (2007) Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 30(suppl 15):5–13

26.

Tolle T, Zu Z, Sadosky AB (2006) Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications 20:26–33PubMed

27.

Zelman D, Core M, Dukes E, Tai K, Brandenburg N (2005) Validation of a modified version of the brief pain inventory for painful diabetic peripheral neuropathy. J Pain Symptom Manage 29:401–410PubMed

28.

Jensen MP, Hoffman AJ, Cardenas DD (2005) Chronic pain in individuals with spinal cord injury: a survey and longitudinal study. Spinal Cord 43:704–712PubMed

29.

Bergbom-Engberg I, Grondahl G, Thibom K (1995) Patients’ experiences of herpes zoster and postherpetic neuralgia. J Adv Nurs 21:427–433

30.

Galer B, Gianas A, Jensen M (2000) Painful diabetic polyneuropathy: epidemiology, pain, description, and quality of life. Diabetes Res Clin Pract 47:123–128PubMed

31.

Tasmuth T, von Smitten K, Hietanen P et al (1995) Pain and other symptoms after different treatment modalities of breast cancer. Ann Oncol 6:453–459PubMed

32.

Flier J, Van Muiswinkel FL, Jongenen CA et al (2002) The neuroprotective antioxidant alpha-lipoic acid induces detoxication enzymes in cultured astroglail cells. Free Radic Res 36:695–699PubMed

33.

Bianchi G, Vitali G, Caraceni A et al (2005) Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced peripheral neuropathy to oral acetyl-L-carnitine. Eur J Cancer 41:1746–1750PubMed

34.

Tankova T, Cherninkova S, Koev D (2005) Treatment for diabetic mononeuropathy with alpha-lipoic acid. Int J Clin Pract 59:645–650PubMed

35.

Eckel F, Schmelz R, Adelsberger H et al (2002) Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study. Dtsch Med Wochenchr 127:78–82

36.

Sindrup S, Jensen T (1999) Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 83:389–400PubMed

37.

Goodman LS, Limbird LE, Milinoff PB et al (eds) (1996) Goodman and Gilman’s: the pharmacological basis of therapeutics, 9th edn. McGraw-Hill Professional, New York

38.

Jensen TS (2002) Anticonvulsants in neuropathic pain. Eur J Pain 6(Suppl A):61–68PubMed

39.

Backonja M, Beydoun A, Edwards KR et al (1978) Gabapentin for the symptomatic treatment of painful neuropathy. J Assoc Physicians India 26(5):403–406

40.

Rao RD, Michalak JD, Sloan JA et al (2007) Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy. Cancer 110:2110–2118PubMed

41.

Gatti G, Bonomi I, Jannuzzi G et al (2000) The new antiepileptic drugs: pharmacological and clinical aspects. Curr Pharm Des 6:839–860PubMed

42.

Gwag BJ, Sessler FM, Robine V et al (1997) Endogenous glutamate levels regulate nerve growth factor mRNA expression in the rat denate gyrus. Mol Cells 7:425–430PubMed

43.

De Santis S, Pace A, Bove L et al (2000) Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin Cancer Res 6:90–95PubMed

44.

Bailey HH, Gipp JJ, Ripple M, Wilding G, Mulcahy RT (1992) Increase in gamma-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels. Cancer Res 52:5115–5118PubMed

45.

Britten RA, Green JA, Warenius HM (1992) Cellular glutathione (GSH) and glutathione S-transferase (GST) activity in human ovarian tumor biopsies following exposure to alkylating agents. Int J Radiat Oncol Biol Phys 24:527–531PubMed

46.

Joncourt F, Oberli-Schrammli AE, Stadler M et al (1995) Patterns of drug resistance parameters in adult leukemia. Leuk Lymph 17:101–109

47.

Perry RR, Mazetta JA, Levin M, Barranco SC (1993) Glutathione levels and variability in breast tumors and normal tissue. Cancer 72:783–787PubMed

48.

Redmond SM, Joncourt F, Buser K et al (1991) Assessment of P-glycoprotein, glutathione-based detoxidying enzymens and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res 51:2092–2097PubMed

49.

Mulder TP, Manni JJ, Roelofs HM, Peters WH, Wiersma A (1995) Glutathione S-transferases and glutathione in human head and neck cancer. Carcinogenesis 16:619–624PubMed

50.

Cook JA, Pass HI, Iype SN et al (1991) Cellular glutathione and thiol measurements from surgically resected human lung tumor and normal lung tissue. Cancer Res 51:4287–4294PubMed

51.

Suzuki T, Nishio K, Tanabe S (2001) The MRP family and anticancer drug metabolism. Curr Drug Metab 2:367–377PubMed

52.

Kawai H, Kiura K, Tabata M et al (2002) Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy. Lung Cancer 35:305–314PubMed

53.

Smyth JF, Bowman A, Parren T et al (1997) Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomized trial. Ann Oncol 8:569–573PubMed

54.

Cascinu S, Cordella L, Del Ferro E et al (1995) Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 13:26–32PubMed

55.

Eisenberg E, Lurie Y, Braker C et al (2001) Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 57:505–509PubMed

56.

Canavero S, Bonicalz V (1996) Lamotrigine control of central pain. Pain 68:179–181PubMed

57.

Renno SI, Rao RD, Sloan J et al (2006) The efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase III randomized, double blind, placebo-controlled NCCTG trial, N01C3. J Clin Oncol 24(185):8530

58.

Saudek CD, Werns S, Reidenberg MM (1977) Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther 22(2):196–199PubMed

59.

Tremont-Lukats IW, Megeff C, Backonja MM (2000) Anticonvulsants for neuropathic pain syndromes: Mechanisms of action and place in therapy. Drugs 60:1029–1052PubMed

60.

Wilson RH, Lehky T, Thomas RR et al (2002) Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20:1767–1774PubMed

61.

Traber MG (2006) Vitamin E. In: Shils ME, Shike M, Ross AC, Caballero B, Cousins R (eds) Modern nutrition in health and disease, 10th edn. Lippincott Williams & Wilkins, Baltimore, pp 396–411

62.

Argyriou AA, Chroni E, Koutras A et al (2005) Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 64:26–31PubMed

63.

Pace A, Savarese A, Picardo M et al (2003) Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 21:927–931PubMed

64.

Jacobs EJ, Henion AK, Briggs PJ et al (2002) Vitamin C and vitamin E supplement use and bladder cancer mortality in a large cohort of US men and women. Am J Epidemiol 156:1002–1010PubMed

65.

Moore DH, Donnelly J, McGuire WP et al (2003) Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neuropathy: a phase II study of the Gynecologic Oncology Group. J Clin Oncol 21:4207–4213PubMed

66.

Nelson DF, Gillespie BW, Diener MD et al (1984) Is misonidazole neurotoxicity altered by the use of phenytoin and/or dexamethasone in ROTG 79-18 and RTOG 79-16? Int J Radiat Oncol Biol Phys 10:1731–1734PubMed

67.

Bergouignan FX, Vital C, Henry P et al (1988) Disulfiram neuropathy. J Neurol 235:382–383PubMed

68.

Lehky TJ, Leonard GD, Wilson RH et al (2004) Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29:387–392PubMed

69.

Davis ID, Kiers L, MacGregor L et al (2005) A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res 11:1890–1898PubMed

70.

Hamers FP, van der Hoop RG, Steerenburg PA et al (1991) Putative neurotrophic factors in the protection of cisplatin-induced peripheral neuropathy in rats. Toxicol Appl Pharmacol 111:514–522PubMed

71.

Roberts JA, Jenison EL, Kim K et al (1997) A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol 67:172–177PubMed

72.

Markes M, Brockow T, Resch KL (2008) Exercise for women receiving adjuvant therapy for breast cancer (Review). The Cochrane Collection, Published by Wiley Ltd in The Cochrane Library, Issue 4

73.

Irwin ML, Crumley D, McTiernan A, Bernstein L, Baumgartner R, Gilliland FD, Kriska A, Ballard-Barbash R (2003) Physical activity levels before and after a diagnosis of breast carcinoma: the Healthy Eating, Activity, and Lifestyle (HEAL) study. Cancer 97(7):1746–1757PubMed

74.

Herrero F, San Juan AF, Fleck SJ, Balmer J, Perez M, Canete S, Earnest CP, Foster C, Lucia A (2005) Combined aerobic and resistance training in breast cancer survivors: a randomized, controlled pilot trial. Int J Sports Med 26(4):294–302PubMed

75.

Aitken DR, James AG (1997) Seromas and physiotherapy after mastectomy. Ann Surg Oncol 4(4):293–297

76.

Schneider CM, Dennehy CA, Roozeboom M, Carter SD (2002) A model program: exercise intervention for cancer rehabilitation. Integr Cancer Ther 1:76–82PubMed

77.

Schneider CM, Hsieh CC, Sprod LK, Carter SD, Hayward R (2007) Effects of supervised exercise training on cardiopulmonary function and fatigue in breast cancer survivors during and after treatment. Cancer 110:918–925PubMed

78.

Schneider CM, Hsieh CC, Sprod LK, Carter SD, Hayward R (2007) Exercise training manages cardiopulmonary function and fatigue during and following cancer treatment in male cancer survivors. Integr Cancer Ther 6(3):235–241PubMed

79.

Schneider CM, Hsieh CC, Sprod LK, Carter SD, Hayward R (2007) Cancer treatment-induced alterations in muscular fitness and quality of life: The role of exercise training. Ann Oncol 18:1957–1962PubMed

80.

Balducci S, Iacobellis G, Parisi L, Di Biase N, Calandriello E, Leonetti F, Fallucca F (2006) Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Its Complicat 20:216–223

81.

Richardson J, Sandman D, Vela S (2001) A focused exercise regimen improves clinical measures of balance in patients with peripheral neuropathy. Arch Phys Med Rehabil 82:205–209PubMed

82.

Tesfaye S, Harris ND, Wilson RM, Ward JD (1992) Exercise-induced conduction velocity increment: a marker of impaired peripheral nerve blood flow in diabetic neuropathy. Diabetologia 35:155–159PubMed

83.

Lindeman E, Leffers P, Spaans F, Drukker J, Reulen J, Kerckhoffs M, Koke A (1995) Strength training in patients with myotonic dystrophy and hereditary motor and sensory neuropathy: a randomized clinical trial. Arch Phys Med Rehabil 76(7):612–620PubMed

84.

Kilmer DD, McCroy MA, Wright NC, Aitkens SG, Bernauer EM (1994) The effect of a high resistance exercise program in slowly progressive neuromuscular disease. Arch Phys Med Rehabil 75(5):560–563PubMed

85.

Aitkens SG, McCrory MA, Kilmer DD, Bernauer EM (1993) Moderate resistance exercise program: its effect in slowly progressive neuromuscular disease. Arch Phys Med Rehabil 74(7):711–715PubMed

86.

Lindeman E, Leffers P, Reulen J, Spaans F, Drukker J (1998) Quadriceps strength and timed motor performances in myotonic dystrophy, Charcot-Marie-Tooth disease, and healthy subjects. Clin Rehabil 12(2):127–135PubMed

87.

Boulton AJM, Malik RA, Arezzo JC, Sosenko JM (2004) Diabetic somatic neuropathies. Diabetes Care 27:1458–1486PubMed

88.

Yong J, Loukianov E, Loukianova T, Jones LR, Periasamy M (1999) SERCA1a can functionally substitute for SERCA2a in the heart. Am J Physiol 276:H89–H97

89.

Wu KD, Lee WS, Wey J, Bungard D, Lytton J (1995) Localization and quantification of endoplasmic reticulum Ca2+-ATPase isoform transcripts. Am J Physiol 269:C775–C784. Cell Physiol 38PubMed

90.

Kleuber KM, Feczko JD (1994) Ultrastructural, histochemical, and morphometric analysis of skeletal muscle in a murine model of type I diabetes. Anat Rec 239:18–34

91.

Racz G, Szabo A, Ver A, Zador E (2009) The slow sarco/endoplasmic reticulum Ca²⁺-ATPase declines independently of slow myosin in soleus muscle of diabetic rats. Acta Biochim Pol 56:487–493PubMed

92.

Baselga J (2001) Herceptin® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 61(suppl 2):14–21PubMed

93.

Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61:203–212PubMed

94.

Samantha A, LeVea CM, Dougall WC, Quian X, Greene MI (1994) Ligand and p185^c-neu density govern receptor interactions and tyrosine kinase activation. Proc Natl Acad Sci USA 91:1711–1715

95.

McGuire JF, Ruen S, Siegfreid E, Wright DE, Dobrowsky RT (2009) Caveolin-1 and altered neuregulin signaling contribute to the pathophysiological progression of diabetic peripheral neuropathy. Diabetes 58:2677–2686PubMed

96.

Yatime L, Buch-Pedersen MJ, Musgaard M et al (2009) P-type ATPases as drug targets: tools for medicine and science. Biophysica Acta 1787:207–220

97.

Cook-Burns N (2001) Retrospective analysis of the safety of Herceptin^® immunotherapy in metastatic breast cancer. Oncology 61(suppl 2):58–66

98.

Feldman AM, Lorell BH, Reis SE (2000) Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation 102:272–274PubMed

99.

Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE (2003) The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 100(15):8933–8938PubMed

100.

Gustafsson T, Puntschart A, Kaijser L, Lansson E, Sundberg CJ (1999) Exercise-induced expression of angiogenesis-related transcription and growth factors in human skeletal muscle. Am J Physiol 276:H679–H685PubMed

101.

Fukai T, Siegfried MR, Ushio-Fukai M, Cheng Y, Kojda G, Harrison DG (2000) Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. J Clin Invest 105:1631–1639PubMed

102.

Wisloff U, Loennechen JP, Falck G, Veisvag V, Currie S, Smith G, Ellingsen O (2001) Increased contractility and calcium sensitivity in cardiac myocytes isolated from endurance trained rats. Cardiovasc Res 50:495–508PubMed

103.

Tate CA, Taffet GE, Hudson EK, Blaylock SL, McBride RP, Michael LH (1990) Enhanced calcium uptake of cardiac sarcoplasmic reticulum in exercise-trained old rats. Am J Physiol 258:H431–H435. Heart Circ Physiol 27PubMed

104.

Tate CA, Helgason T, Hyek MF, McBride RP, Chen M, Richardson MA, Taffet GE (1996) SERCA2a and mitochondrial cytochrome oxidase expression are increased in hearts of exercise-trained old rats. Am J Physiol 271:H68–H72. Heart Circ Physiol 40PubMed

105.

Wonders KY, Hydock DS, Greufe S, Schneider CM, Hayward R (2009) Endurance training preserves cardiac function in rats receiving doxorubicin and the HER2-inhibitor GW2974. Cancer Chemother Pharmacol 64(6):1105–1113PubMed

106.

Obrosova IG, Drel VR, Pacher P et al (2005) Oxidative-nitrosative stress and poly(ADP-Ribose) polymerase PPARP) activation in experimental diabetic neuropathy: the relation is revisited. Diabetes 54:3435–3441PubMed

107.

Obrosova IG, Drel VR, Oltman CL et al (2007) Rose of nitrosative stress in early neuropathy and vascular dysfunction in streptozotcin-diabetic rats. Am J Physiol Endocrinol Metab 293:E1645–E1655PubMed

108.

Koltyn KF, Wertz AL, Gardiner RL et al (1996) Perception of pain following aerobic exercise. Med Sci Sports Exerc 28:1418–1421PubMed

109.

Gurevich M, Kohn PM, Davis C (1994) Exercise-induced analgesia and the role of reactivity in pain sensitivity. J Sports Sci 12:549–559PubMed

110.

Sternberg WF, Bokat C, Kass L et al (2001) Sex-dependent components of the analgesia produced by athletic competition. Pain 94:65–74

111.

Sternberg WF, Bailin D, Grant M et al (1998) Competition alters the perception of noxious stimuli in male and female athletes. Pain 76:231–238PubMed

112.

Haier RJ, Quaid K, Mills JSC (1981) Naloxone alters pain perception after jogging. Psychiatry Res 5:231–232PubMed

113.

Koltyn KF, Arbogast RW (1998) Perception of pain after resistance exercise. Br J Sports Med 32:20–24PubMed

114.

Carter GT, Kikuchi N, Abresch RT, Walsh SA, Horasek S, Fowler WM (1994) Effects of exhaustive concentric and eccentric exercise on murine skeletal muscle. Arch Phys Med Rehabil 75:555–559PubMed

115.

Carter GT, Abresch RT, Fowler WM (2002) Adaptations to exercise training and contraction-induced muscle injury in animal models of neuromuscular disease. Am J Phys Med Rehabil 81(suppl):S151–S161PubMed

116.

Breslin E, Booth J, Lord B et al (1993) Respiratory responses to unsupported arm exercise (UAE) in Charcot Marie Tooth (CMT) [abstract]. American Thoracic Society. Am Rev Respir Dis 147:A532

Title: Treatment strategies for chemotherapy-induced peripheral neuropathy: potential role of exercise
Authors: Karen Y. Wonders
Beverly S. Reigle
Daniel G. Drury
Publication date: 01-06-2010
Publisher: Springer Milan
Published in: Oncology Reviews / Issue 2/2010
Print ISSN: 1970-5557
Electronic ISSN: 1970-5565
DOI: https://doi.org/10.1007/s12156-010-0044-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Paclitaxel induced chronic fibrosing interstitial pneumonitis: a case report and review of the literature

Common soil of smoking-associated and hormone-related cancers: estrogen deficiency

Alteration to the SWI/SNF complex in human cancers

Management of paclitaxel-induced neurotoxicity

Gastric carcinoma: when is palliative gastrectomy justified?

The dark side of paclitaxel

Keynote webinar | Spotlight on antibody–drug conjugates in cancer